ACER Key Statistics, Chart & Performance
The current stock price of ACER is 0.9 USD. In the past month the price increased by 20%. In the past year, price decreased by -26.83%.
ACER Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.39 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.73 | 493.40B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.22B | ||
| PFE | PFIZER INC | 7.95 | 144.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.3 | 110.79B | ||
| ZTS | ZOETIS INC | 20.4 | 57.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.89 | 23.46B | ||
| VTRS | VIATRIS INC | 5.32 | 14.28B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.79 | 11.83B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.59B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About ACER
Company Profile
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Company Info
ACER THERAPEUTICS INC
One Gateway Center (300 Washington St.), Suite 356
Newton MASSACHUSETTS 02458 US
CEO: Chris Schelling
Employees: 33
Phone: 18449026100.0
ACER THERAPEUTICS INC / ACER FAQ
Can you describe the business of ACER THERAPEUTICS INC?
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
What is the stock price of ACER THERAPEUTICS INC today?
The current stock price of ACER is 0.9 USD. The price increased by 3.41% in the last trading session.
Does ACER stock pay dividends?
ACER does not pay a dividend.
What is the ChartMill rating of ACER THERAPEUTICS INC stock?
ACER has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of ACER THERAPEUTICS INC (ACER) based on its PE ratio?
ACER THERAPEUTICS INC (ACER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
Can you provide the market cap for ACER THERAPEUTICS INC?
ACER THERAPEUTICS INC (ACER) has a market capitalization of 22.01M USD. This makes ACER a Nano Cap stock.
ACER Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACER. When comparing the yearly performance of all stocks, ACER turns out to be only a medium performer in the overall market: it outperformed 51.09% of all stocks.
ACER Financial Highlights
Over the last trailing twelve months ACER reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -88.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -225.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACER Forecast & Estimates
8 analysts have analysed ACER and the average price target is 1.53 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 0.9.